Strontium Ranelate
Indication
Primary and secondary prevention of osteoporotic fragility fractures in postmenopausal women (NICE TA160 & 161)
EMA April 2014 - Protelos/Osseor to remain available but with further restrictions
MHRA Drug Safety Update - Strontium ranelate: cardiovascular risk—restricted indication and new monitoring requirements (March 2014)
Amber level 0
Brand:
Nice TA:
160, 161
Commissioning responsibility:
CCG
PbR excluded:
No
BNF chapter:
Endocrine system
Background
The EMA has considered that strontium ranelate should only be used by people for whom there are no other treatments for osteoporosis. The cardiovascular risks identified with strontium ranelate may be sufficiently reduced in this population by restricting its use to people without cardiovascular contraindications. Please see link to the Drug Safety Update on the MHRA website for further information (in supporting documents below)
Recommendation
LSCMMG Recommendation:
Amber level 0
Reason for decision:
Suitable for GP prescribing following recommendation/initiation by specialist
Supporting documents: